UPDATE: CRT Capital Initiates Coverage on Covidien plc. at Buy, Announces $82.00 PT

Loading...
Loading...
CRT Capital initiated coverage of Covidien
COV
with a Buy rating and $82 price target. Shagun Chadha, analyst at CRT, believes the company “has a full pipeline and a road map to tap into five potentially $1+ billion high growth markets each.” Shares have moved in a straight line higher since the open, now up about 1.4 percent to $71.34. Chadha said Covidien can “consistently deliver 4-6% revenue growth lead by: a) an improvement in revenue mix towards higher-growth segments and geographies, b) new products introductions, and c) an appetite for strategic acquisitions.” The analyst credited “solid execution” to the company's superb operational leverage, which, in addition to a non-US tax structure, provides “access to more cash to return to shareholders than its large cap medical technology peers.” Chadha's projection “calls for 9-13% EPS growth [through 2017] with leverage from its restructuring programs.”
Posted In: Analyst ColorNewsPrice TargetInitiationAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...